Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 10/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 5/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.37 |
| ▸ | DNMT3A | Q9Y6K1 | 4/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8055904 | 0.90 | MLYCD (0.35) | CSNK1DEHMT2KDM4EEHMT1 | |
| SCHEMBL8065929 | 0.86 | CSNK1D (0.34) | CSNK1DCSNK1EEHMT2ALKKDM4E | |
| SCHEMBL8023727 | 0.86 | MAPK1 (0.36) | EHMT2ALKEHMT1 | |
| SCHEMBL15317967 | 0.85 | MAPK14 (0.32) | CSNK1DEHMT2 | |
| SCHEMBL12892440 | 0.85 | PIK3CD (0.42) | CSNK1D | |
| SCHEMBL12879883 | 0.85 | PIK3CD (0.42) | CSNK1D | |
| SCHEMBL194991 | 0.85 | PDE4D (0.35) | EHMT2DNMT3AALKEHMT1 | |
| SCHEMBL12872258 | 0.85 | SMN1; SMN2 (0.36) | EHMT2DNMT3AALKMEN1ALDH1A1 | |
| SCHEMBL187845 | 0.84 | OPRL1 (0.42) | EHMT2EHMT1 | |
| SCHEMBL10265576 | 0.84 | EML4 (0.36) | EHMT2DNMT3AALKEHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2214673-B1 | PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2012-05-30 | — | — | EP | disclosed |
| US-20110028441-A1 | NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028441-A1 | NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028441-A1 | NOVEL PHENYL-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, DPM1, DDX41 | CSNK1D 3651/4885CSNK1E 4156/4885EHMT2 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.